Startseite
Impressum
Datenschutz
 
 
  SPOT ON
 

Passing bell for Rosiglitazone (AVANDIA)?

 
  NEW ON THE MARKET
 

COPD: phosphodiesterase-4 inhibitor roflumilast (DAXAS)

Me too: alpha blocker silodosin (UROREC) for prostatic hyperplasia

 
  THERAPY FROM A CRITICAL VIEWPOINT

Bevacizumab (AVASTIN) without benefit in breast cancer

 
  a-t READER'S QUESTIONS AND COMMENTS
 

Novo Nordisk: foregoing profit for the benefit of patients?

 
  IN BRIEF
 

"Flu" vaccines for 2010/11

Alteplase (ACTILYSE) for acute ischemic stroke

Celecoxib (CELEBREX) better than diclofenac (VOLTAREN, generics) plus omeprazole (ANTRA, generics)?

Tranexamic acid (CYKLOKAPRON) use for severe trauma

 
  SIDE EFFECTS
 

Prescription required for topical ketoprofen (e.g. ADVEL pain relieving gel)

Serious liver injury due to leflunomide (ARAVA)

Modafinil (VIGIL) soon restricted to narcolepsy only?

 
  CURRENT ADR NETWORK REPORT
 

Liver injury due to dronedarone (MULTAQ)?

 
  DOCUMENTATION
 

Rise and fall of the glitazone rosiglitazone (AVANDIA)

 
© arznei-telegramm 8/2010